Please wait a minute...
Reviews in Cardiovascular Medicine  2014, Vol. 15 Issue (2): 86-101     DOI: 10.3909/ricm0741
Review Previous articles | Next articles
Management of Hypercholesterolemia for Prevention of Atherosclerotic Cardiovascular Disease: Focus on the Potential Role of Recombinant Anti-PCSK9 Monoclonal Antibodies
Divya Ratan Verma1, Eliot A. Brinton2
1 Division of Cardiology, University of Utah School of Medicine
2 Utah Foundation for Biomedical Research, Salt Lake City, UT
Download:  PDF(779KB)  ( 153 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability in the United States and other developed nations, and is rising rapidly in the rest of the world. Low-density lipoprotein (LDL) is the major atherogenic particle in most patients at high risk for ASCVD events, and statin-based LDL-lowering treatment is the major focus of treatment for prevention of ASCVD. Despite this, an estimated 57 million US adults (25%) still have moderately elevated levels of LDL-cholesterol (LDL-C) > 160 mg/dL, and many others have an LDL-C above the level considered appropriate for their high-risk status. Although statins are very effective for lowering LDL-C, and other classes of LDL-lowering medications are available, many patients still cannot achieve adequate LDL-lowering with maximal tolerated doses of US Food and Drug Administration–approved treatments. Thus, there is an unmet medical need for statin adjuncts in these patients, as well as for statin alternatives in statin-intolerant patients. A recently discovered human protein, proprotein convertase subtilisin/kexin type 9 (PCSK9), plays an important role in LDL metabolism by promoting degradation of the LDL receptor, and thus reducing clearance of LDL and increasing LDL-C levels. Accordingly, inhibition of PCSK9 activity has become an attractive target for drug development for lowering LDL-C, and human monoclonal antibodies against PCSK9, are now in late-stage clinical development. These antibodies are at least as effective as statins for LDL-C lowering (or more so), and their effects are additive to those of statins. To date, they have been well tolerated and apparently safe in clinical trials. Long-term randomized, controlled trials of their safety, tolerability, and ability to reduce ASCVD are now underway.
Key words:  Hypercholesterolemia      Atherosclerotic cardiovascular disease      PCSK9      Low-density lipoprotein     
Published:  30 June 2014     

Cite this article: 

Divya Ratan Verma, Eliot A. Brinton. Management of Hypercholesterolemia for Prevention of Atherosclerotic Cardiovascular Disease: Focus on the Potential Role of Recombinant Anti-PCSK9 Monoclonal Antibodies. Reviews in Cardiovascular Medicine, 2014, 15(2): 86-101.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm0741     OR     https://rcm.imrpress.com/EN/Y2014/V15/I2/86

[1] Rudaynah A. Alali. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 1-8.
[2] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[3] Jennifer G. Robinson, Karol E. Watson. Can We Cure Atherosclerosis?[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 20-24.
[4] Seth J. Baum, Alan S. Brown. Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 25-30.
[5] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31-46.
[6] Sivakumar Sudhakaran, Teodoro Bottiglieri, Kristen M. Tecson, Aaron Y. Kluger, Peter A. McCullough. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions[J]. Reviews in Cardiovascular Medicine, 2018, 19(3): 77-88.
[7] Jane I. Won, Jun Zhang, Kristen M. Tecson , Peter A. McCullough. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2017, 18(1): 21-28.
[8] Seth J. Baum, Daniel Soffe, P. Barton Duell. Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2016, 17(1-2): 16-27.
[9] Boback Ziaeian, John Dinkler, Karol Watson. Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 125-130.
[10] Norman E. Lepor, Laurn Contreras, Chirag Desai, Dean J. Kereiakes. The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 290-309.
[11] Karol E. Watson, Eric H. Stocker, Douglas S. Jacoby, Peter A. McCullough. Advanced Lipid Testing: When, Why, and In Whom?[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 310-319.
[12] Emil M. deGoma. Lomitapide for the Management of Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 109-118.
[13] Peter P. Toth, Prediman K. Shah, Michael J. Wilkinson, Michael H. Davidson, Peter A. McCullough. Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice[J]. Reviews in Cardiovascular Medicine, 2014, 15(1): 1-10.
[14] Vasilios Papademetriou. Cardiovascular Protection Paradigms: Is Change on the Horizon?[J]. Reviews in Cardiovascular Medicine, 2007, 8(4): 200-213.
[15] Thomas M. Bashore, David P. Faxon, Norman E. Lepor, Prediman K. Shah, Karol E. Watson, Arthur E. Weyman. Best of the ACC 2007 Scientific Sessions[J]. Reviews in Cardiovascular Medicine, 2007, 8(2): 101-117.
No Suggested Reading articles found!